Kalaris Therapeutics, Inc. KLRS
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 12.35% | -- | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -29.34% | -- | -- | -- | -- |
| Operating Income | 29.34% | -- | -- | -- | -- |
| Income Before Tax | 45.79% | -- | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 45.79% | -- | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 45.79% | -- | -- | -- | -- |
| EBIT | 29.34% | -- | -- | -- | -- |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 95.60% | -- | -- | -- | -- |
| Normalized Basic EPS | 95.60% | -- | -- | -- | -- |
| EPS Diluted | 95.60% | -- | -- | -- | -- |
| Normalized Diluted EPS | 95.60% | -- | -- | -- | -- |
| Average Basic Shares Outstanding | 236.52% | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | 236.52% | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |